Rarely do I see it mentioned that the guy who introduced Lovaza, (Omacor), to the market is now the CEO of Amarin. That introduction was legendary and a huge success. Rarely do I see it mentioned that although the "fish oil pill" market for Lovaza is contracting, (thus apparently indicating trouble for Vascepa), the reason for the contraction is due to Lovaza not being too great for heart attacks and strokes. Lovaza raises LDL levels which lead to more heart attacks and strokes. Vascepa doesn't do that, it just does the good things that Lovaza does. Vascepa will expand this market again. Rarely do I see it mentioned that very recently several companies were said to be in talks with Amarin for prices between $20-$30, YES. They are still interested. $8.52? Come on, grow a brain.. At least I hear a lot about the multi-billion dollar market for ANCHOR, which doesn't seem to be factored into much of anything?
One of the reasons I loaded up on AMRN is because of the CEO and his track record. It is one on the majorly important things I look for in biotech - a successful track record. See also RXII for similar CEO success and the Nobel Prize winning chief scientist there. Without a track record of success, it is much more of a guess as to whether the leadership can drive the drug to success.